NeurAxis Investor Relations Material
Latest events
Q1 2025
NeurAxis
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from NeurAxis Inc
Access all reports
NeurAxis, Inc. is a medical technology company specializing in neuromodulation therapies aimed at addressing chronic and debilitating conditions in both children and adults. The company’s primary product, IB-Stim, utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) technology to alleviate functional abdominal pain associated with irritable bowel syndrome (IBS) in patients aged 11 to 18. The company is headquartered in Carmel, Indiana, and its shares are listed on the NYSE American.
Key slides for NeurAxis Inc
Q3 2024
NeurAxis Inc
Q4 2024
NeurAxis Inc
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
NRXS
Country
🇺🇸 United States